GNI Group Ltd. (2160.T)
JPY 2415.0
(1.05%)
JPY 2415.0
(1.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.32 Billion JPY | 33.55% |
| 2022 | 13.36 Billion JPY | 41.22% |
| 2021 | 9.46 Billion JPY | 48.86% |
| 2020 | 6.35 Billion JPY | 24.85% |
| 2019 | 5.09 Billion JPY | 41.39% |
| 2018 | 3.6 Billion JPY | 80.17% |
| 2017 | 1.99 Billion JPY | 43.46% |
| 2016 | 1.39 Billion JPY | -1.08% |
| 2015 | 1.4 Billion JPY | 63.02% |
| 2014 | 864.22 Million JPY | 7.71% |
| 2013 | 802.39 Million JPY | 60.75% |
| 2012 | 499.17 Million JPY | 5.05% |
| 2011 | 475.18 Million JPY | -1.01% |
| 2010 | 480.03 Million JPY | 0.0% |
| 2008 | 981.58 Million JPY | -29.22% |
| 2007 | 1.38 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.55 Billion JPY | 14.64% |
| 2024 Q1 | 3.97 Billion JPY | -38.98% |
| 2023 Q2 | 4.04 Billion JPY | 24.99% |
| 2023 Q3 | 4.09 Billion JPY | 1.32% |
| 2023 FY | 17.85 Billion JPY | 33.55% |
| 2023 Q1 | 3.23 Billion JPY | -19.26% |
| 2023 Q4 | 6.51 Billion JPY | 59.08% |
| 2022 Q1 | 2.9 Billion JPY | -6.22% |
| 2022 Q3 | 3.34 Billion JPY | 7.51% |
| 2022 Q4 | 4 Billion JPY | 19.82% |
| 2022 FY | 13.36 Billion JPY | 41.22% |
| 2022 Q2 | 3.11 Billion JPY | 7.07% |
| 2021 Q3 | 2.14 Billion JPY | 35.57% |
| 2021 Q1 | 2.64 Billion JPY | 36.12% |
| 2021 Q2 | 1.58 Billion JPY | -40.19% |
| 2021 FY | 9.46 Billion JPY | 48.86% |
| 2021 Q4 | 3.09 Billion JPY | 44.55% |
| 2020 Q1 | 1.33 Billion JPY | -10.59% |
| 2020 Q2 | 1.44 Billion JPY | 8.49% |
| 2020 Q3 | 1.63 Billion JPY | 13.35% |
| 2020 Q4 | 1.94 Billion JPY | 18.5% |
| 2020 FY | 6.35 Billion JPY | 24.85% |
| 2019 Q3 | 1.25 Billion JPY | -1.13% |
| 2019 Q1 | 1.07 Billion JPY | 8.37% |
| 2019 FY | 5.09 Billion JPY | 41.39% |
| 2019 Q2 | 1.27 Billion JPY | 18.95% |
| 2019 Q4 | 1.49 Billion JPY | 18.37% |
| 2018 Q2 | 839.94 Million JPY | 9.7% |
| 2018 Q3 | 1 Billion JPY | 20.1% |
| 2018 Q1 | 765.65 Million JPY | 13.13% |
| 2018 FY | 3.6 Billion JPY | 80.17% |
| 2018 Q4 | 987.71 Million JPY | -2.08% |
| 2017 Q1 | 362.53 Million JPY | -14.82% |
| 2017 FY | 1.99 Billion JPY | 43.46% |
| 2017 Q3 | 578.44 Million JPY | 51.64% |
| 2017 Q2 | 381.45 Million JPY | 5.22% |
| 2017 Q4 | 676.81 Million JPY | 17.01% |
| 2016 Q1 | 368.53 Million JPY | -20.2% |
| 2016 Q2 | 319.34 Million JPY | -13.35% |
| 2016 FY | 1.39 Billion JPY | -1.08% |
| 2016 Q4 | 425.61 Million JPY | 51.94% |
| 2016 Q3 | 280.11 Million JPY | -12.28% |
| 2015 FY | 1.4 Billion JPY | 63.02% |
| 2015 Q2 | 319.1 Million JPY | 12.07% |
| 2015 Q1 | 284.73 Million JPY | 4.29% |
| 2015 Q4 | 461.83 Million JPY | 33.19% |
| 2015 Q3 | 346.74 Million JPY | 8.66% |
| 2014 Q3 | 235.85 Million JPY | 31.77% |
| 2014 FY | 864.22 Million JPY | 7.71% |
| 2014 Q4 | 273.02 Million JPY | 15.76% |
| 2014 Q1 | 176.35 Million JPY | -15.25% |
| 2014 Q2 | 178.99 Million JPY | 1.5% |
| 2013 FY | 802.39 Million JPY | 60.75% |
| 2013 Q4 | 208.08 Million JPY | -45.62% |
| 2013 Q1 | 105.79 Million JPY | -13.45% |
| 2013 Q2 | 105.89 Million JPY | 0.09% |
| 2013 Q3 | 382.62 Million JPY | 261.34% |
| 2012 Q1 | 139.55 Million JPY | 1.33% |
| 2012 Q4 | 122.23 Million JPY | 6.28% |
| 2012 Q3 | 115.01 Million JPY | -6.01% |
| 2012 FY | 499.17 Million JPY | 5.05% |
| 2012 Q2 | 122.36 Million JPY | -12.31% |
| 2011 Q1 | 131.75 Million JPY | 16.9% |
| 2011 Q3 | 95.17 Million JPY | -14.95% |
| 2011 FY | 475.18 Million JPY | -1.01% |
| 2011 Q4 | 137.72 Million JPY | 44.71% |
| 2011 Q2 | 111.89 Million JPY | -15.07% |
| 2010 Q1 | 135.86 Million JPY | 0.0% |
| 2010 FY | 480.03 Million JPY | 0.0% |
| 2010 Q4 | 112.71 Million JPY | -0.96% |
| 2010 Q3 | 113.8 Million JPY | -3.27% |
| 2010 Q2 | 117.65 Million JPY | -13.4% |
| 2009 Q3 | 158.75 Million JPY | 9.74% |
| 2009 Q1 | 142.3 Million JPY | -40.06% |
| 2009 Q2 | 144.66 Million JPY | 1.66% |
| 2008 FY | 981.58 Million JPY | -29.22% |
| 2008 Q4 | 237.42 Million JPY | -20.15% |
| 2008 Q3 | 297.32 Million JPY | -4.9% |
| 2008 Q2 | 312.64 Million JPY | 0.0% |
| 2007 FY | 1.38 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -625.771% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -1516.174% |
| Linical Co., Ltd. | 2.7 Billion JPY | -244.609% |
| Trans Genic Inc. | 2.15 Billion JPY | -331.624% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -525.174% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -203.553% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -402.017% |
| AnGes, Inc. | 8.9 Billion JPY | -4.719% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -888.497% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 51.421% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -2157.278% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -855.773% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -263.079% |
| CanBas Co., Ltd. | 278 Million JPY | -3253.357% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -716.649% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -412.794% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -481.279% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -292.674% |
| PeptiDream Inc. | 9.68 Billion JPY | 3.767% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -375.486% |
| Ribomic Inc. | 1.1 Billion JPY | -743.123% |
| SanBio Company Limited | 4.53 Billion JPY | -105.383% |
| Healios K.K. | 3.48 Billion JPY | -167.345% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -707.311% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -598.582% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -564.238% |
| StemRIM | 2.07 Billion JPY | -349.053% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -374.782% |
| FunPep Company Limited | 313.82 Million JPY | -2870.589% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -873.091% |
| Stella Pharma Corporation | 963.98 Million JPY | -867.062% |
| TMS Co., Ltd. | 943.25 Million JPY | -888.317% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -755.297% |
| Cuorips Inc. | 598.11 Million JPY | -1458.611% |
| K Pharma,Inc. | 543.94 Million JPY | -1613.847% |
| Takara Bio Inc. | 23.9 Billion JPY | 61.003% |
| ReproCELL Incorporated | 1.51 Billion JPY | -515.736% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -687.366% |
| StemCell Institute Inc. | 1.16 Billion JPY | -702.182% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -512.394% |
| CellSeed Inc. | 804.93 Million JPY | -1058.153% |